Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Pfizer Inc. : Pfizer CEO 2011 Compensation Valued At $25 Million, Up 44% Vs 2010

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/15/2012 | 10:07pm CET
  By Peter Loftus 
  Of  
 

Pfizer Inc. (>> Pfizer Inc.) Chief Executive Ian Read received compensation valued at $25 million for 2011, up 44% from 2010, largely reflecting his promotion to the drug maker's top executive post in December 2010.

Read's compensation also was based partly on Pfizer exceeding targets set by the board's compensation committee for 2011 revenue, adjusted earnings and cash flow from operations, according to a proxy statement filed Thursday with the U.S. Securities and Exchange Commission.

The compensation committee cited Read's role in pursuing divestitures of noncore businesses and in returning cash to shareholders through dividends and share repurchases. Pfizer shares rose 23.6% for 2011.

Read, 58 years old, took over as Pfizer CEO in December 2010 when Jeffrey Kindler unexpectedly left the company. Read added the title of chairman of the board in December 2011.

For 2011, several elements of Read's compensation increased considerably. Stock awards rose to $5.7 million from $2.7 million, while the value of option awards surged to $6.9 million from less than $1 million, according to the proxy.

Read's salary was $1.7 million and his non-equity incentive plan compensation was $3.5 million. Other elements of his compensation: $6.9 million change in pension value and non-qualified deferred compensation earnings, and $319,000 in all other compensation.

For 2012, Read's salary will increase to $1.75 million, Pfizer said in the proxy.

Read, who joined Pfizer in 1978, has accumulated pension benefits with a total present value of about $27.4 million. In addition, the aggregate balance of Read's non-qualified deferred compensation is $8.2 million.

Pfizer Chief Financial Officer Frank D'Amelio received total compensation valued at $7.7 million for 2011, versus $6.5 million in 2010. Mikael Dolsten, president of worldwide research and development, received 2011 compensation valued at $7 million, up from $5.9 million for 2010.

Pfizer also disclosed in its proxy that its board compensation committee has made certain changes in executive pay in response to a disappointing shareholder advisory vote on executive compensation at last year's annual meeting.

The company has modified the terms of performance share awards so that they'll align more closely with performance, and has provided more a detailed explanation of its performance metrics, according to the proxy.

The compensation committee attributed the disappointing advisory vote at last year's annual shareholder meeting to dissatisfaction with the separation agreement with Kindler in late 2010. That agreement included a cash severance payment of $4.5 million and other compensation.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
09:38a Merck KGaA and Pfizer break into cancer immunotherapy
09:18a Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio
03/24 GLOBAL GLAUCOMA THERAPEUTICS MARKET : Allergan, Merck, Novartis, Pfizer, Santen..
03/24 PFIZER : Receives Positive CHMP Opinion for TRUMENBA® for Prevention of Meningoc..
03/24 PFIZER : Doctors Without Borders Urges Pharmaceutical Corporations to Release Cl..
03/24 PFIZER : Receives Positive CHMP Opinion for Trumenba for Prevention of Meningoco..
03/24 PFIZER : FDA Grants Approval for BAVENCIO® (avelumab)
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23 TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Advertisement
Financials ($)
Sales 2017 53 525 M
EBIT 2017 20 455 M
Net income 2017 13 219 M
Debt 2017 25 072 M
Yield 2017 3,76%
P/E ratio 2017 13,99
P/E ratio 2018 13,28
EV / Sales 2017 4,25x
EV / Sales 2018 3,98x
Capitalization 202 474 M
More Financials
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 38,1 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Ole Isacson Chief Scientific Officer
W. Don Cornwell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%202 474
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.60%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results